Search:
in
All Series
Cardiology
Cardiometabolic Disorders
HIV and Other Retroviruses
Hypertension
Neurology and Psychiatry
Oncology
Respiratory Medicine
Viral Hepatitis
Diabetes
Login
Home
Subscriptions
About Us
Authors
Congress Reports
Permissions
Feedback
Contact Us
FBCommunication
|
You are here:
Articles
Hot Topics in ...
Cardiology
Cardiometabolic Disorders
HIV and Other Retroviruses
Hypertension
Neurology and Psychiatry
Oncology
Respiratory Medicine
Viral Hepatitis
Diabetes
HOT TOPICS IN CARDIOLOGY: Issue 4, 2006
The phenomenon of “resistance” to antiplatelet drugs
The phenomenon of resistance to antiplatelet drugs
Carlo Patrono
,
Bianca Rocca
Correspondence to:
Carlo Patrono
- MD
Professor of Pharmacology
Department of Pharmacology
University of Roma "La Sapienza"
Center of Excellence on Aging
"G.D'Annunzio" University Foundation
Chieti, Italy
E-mail:
cpatrono@unich.it
DOI:
Full Text
|
PDF
Summary
THE CONCEPT OF DRUG RESISTENCE AS EXEMPLIFIED BY RESISTANCE TO CHEMOTHERAPY
CLASSIFICATION OF ANTIPLATELET DRUGS BASED ON THEIR MECHANISM OF ACTION
Biochemical aspects of platelet function related to the mechanism of action of antiplatelet drugs
Glycoprotein IIb/IIIa
Platelet arachidonic acid metabolism
Platelet P2Y receptors
Irreversible and reversible inhibitors of platelet COX-1
Irreversible inhibitors: Aspirin
Reversible COX-1 inhibitors
P2Y12 antagonists: thienopyridines and related compounds
Thienopyridines
Other P2Y12 antagonists
Dipyridamole
Blockers of GPIIb/IIIa
Intravenous blockers: abciximab, eptifibatide, and tirofiban
Oral GPIIb/IIIa blockers
TP antagonists
ASSESSMENT OF PLATELET FUNCTION
In vitro and ex vivo assays
The bleeding time
In vitro platelet aggregation in platelet-rich plasma
Platelet aggregation in whole blood
Other assays in whole blood
Membrane markers of platelet activation
Soluble indexes of platelet activation: serum TXB2
In vivo assays
Plasma indexes of platelet activation
Urinary indexes of platelet activation
ASPIRIN "RESISTANCE"
Clinical aspirin resistance
Aspirin resistance defined on the basis of functional end-points
PFA-based studies
LTA-based studies
RPFA-based studies
Aspirin resistance defined on mechanism-based biochemical end-points
CLOPIDOGREL "RESISTANCE"
DETERMINANTS OF THE INTERINDIVIDUAL VARIABILITY IN RESPONSE TO ANTIPLETELET DRUG
Introduction: therapy as a science
Pharmacokinetic variability
Pharmacodynamic variability
CONCLUSIONS
Variability of the response to antiplatelet drugs: implications for the practicing physician
Variability of the response to antiplatelet drugs: implications for the clinical investigator
REFERENCES
If you have a Username and Password, you may already access to this article. Please login below.
Go to login page
If you do not have a Username and Password, click the "Register" button below to purchase this article.
Go to register page
Hot Topics in ...
No additional articles by this author(s) are available in our Series.
PubMed
Articles by
Carlo Patrono
Articles by
Bianca Rocca
Google Scholar
Articles by
Carlo Patrono
Articles by
Bianca Rocca